Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 889-895

  Nyunt, M M ^a,b,c   Lu, Y ^c   Yu, Q ^c   El Gasim, M ^a   Parsons, T L ^c   Petty, B G ^c   Hendrix, C W ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYQUININE; CYTOCHROME P450 3A4; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; LOPINAVIR PLUS RITONAVIR; QUININE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN EXPERIMENT; MALARIA; MALE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; TINNITUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; LOPINAVIR; MIDDLE AGED; QUININE; RITONAVIR; YOUNG ADULT;

EID: 84860003222     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.326     Document Type: Article

References (49)

1. Laufer, M.K. & Plowe, C.V. The interaction between HIV and malaria in Africa. Curr. Infect. Dis. Rep. 9, 47-54 (2007).
2. German, P. et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr. 51, 424-429 (2009).
3. Giao, P.T. & de Vries, P.J. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40, 343-373 (2001).
4. Soyinka, J.O., Onyeji, C.O., Omoruyi, S.I., Owolabi, A.R., Sarma, P.V. & Cook, J.M. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J. Pharm. Pharmacol. 61, 439-443 (2009).
5. Mirghani, R.A., Hellgren, U., Bertilsson, L., Gustafsson, L.L. & Ericsson, O. Metabolism and elimination of quinine in healthy volunteers. Eur. J. Clin. Pharmacol. 59, 423-427 (2003).
6. Pukrittayakamee, S. et al. A study of the factors affecting the metabolic clearance of quinine in malaria. Eur. J. Clin. Pharmacol. 52, 487-493 (1997).
7. Wanwimolruk, S., Wong, S.M., Zhang, H., Coville, P.F. & Walker, R.J. Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment. J. Pharm. Pharmacol. 47, 957-963 (1995).
8. Mukonzo, J.K., Waako, P., Ogwal-Okeng, J., Gustafsson, L.L. & Aklillu, E. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther. Drug Monit. 32, 346-352 (2010).
9. Pussard, E., Merzouk, M. & Barennes, H. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur. J. Pharm. Sci. 32, 123-127 (2007).
10. Silamut, K., Molunto, P., Ho, M., Davis, T.M. & White, N.J. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br. J. Clin. Pharmacol. 32, 311-315 (1991).
11. Oie, S., Jacobson, M.A. & Abrams, D.I. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J. Acquir. Immune Defic. Syndr. 6, 531-533 (1993).
12. Graninger, W., Thalhammer, F., Hollenstein, U., Zotter, G.M. & Kremsner, P.G. Serum protein concentrations in Plasmodium falciparum malaria. Acta Trop. 52, 121-128 (1992).
13. Schön, A., del Mar Ingaramo, M. & Freire, E. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys. Chem. 105, 221-230 (2003).
14. Granfors, M.T., Wang, J.S., Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98, 79-85 (2006).
15. Koudriakova, T. et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26, 552-561 (1998).
16. Foisy, M.M., Yakiwchuk, E.M. & Hughes, C.A. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42, 1048-1059 (2008).
17. Ding, R. et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84 (2004).
18. Perloff, M.D., Von Moltke, L.L., Marchand, J.E. & Greenblatt, D.J. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90, 1829-1837 (2001).
19. Soyinka, J.O., Onyeji, C.O., Omoruyi, S.I., Owolabi, A.R., Sarma, P.V. & Cook, J.M. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br. J. Clin. Pharmacol. 69, 262-270 (2010).
20. Powell, R.D. & McNamara, J.V. Quinine: side effects and plasma levels. Proc. Helminthol. Soc. Wash. 39, 331-338 (1972).
21. Krishna, S. & White, N.J. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet. 30, 263-299 (1996).
22. Dondorp, A.M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009).
23. Oldfield, V. & Plosker, G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 66, 1275-1299 (2006).
24. Lin, J.H. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98 (2003).
25. Piscitelli, S.C. & Gallicano, K.D. Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. 344, 984-996 (2001).
26. Mansor, S.M., Ward, S.A., Edwards, G., Hoaksey, P.E. & Breckenridge, A.M. The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. J. Pharm. Pharmacol. 43, 650-654 (1991).
27. Taylor, W.R. & White, N.J. Antimalarial drug toxicity: a review. Drug Saf. 27, 25-61 (2004).
28. US Food and Drug Administration. KaletraTM (lopinavir/ritonavir) 〈http://www.fda.gov/cder/foi/label/2008/021906s015,021251s024lbl.pdf〉 (2008).
29. US Food and Drug Administration. Qualaquine (quinine sulfate) 〈http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021799s016lbl. pdf〉 (2011).
30. Lefèvre, G. et al. Interaction trial between artemether- lumefantrine (Riamet) and quinine in healthy subjects. J. Clin. Pharmacol. 42, 1147-1158 (2002).
31. White, N.J., Chanthavanich, P., Krishna, S., Bunch, C. & Silamut, K. Quinine disposition kinetics. Br. J. Clin. Pharmacol. 16, 399-403 (1983).
32. Na-Bangchang, K., Tan-Ariya, P., Thanavibul, A., Riengchainam, S., Shrestha, S.B. & Karbwang, J. Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. Int. J. Clin. Pharmacol. Res. 19, 73-82 (1999).
33. Supanaranond, W. et al. Lack of a significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans. R. Soc. Trop. Med. Hyg. 91, 694-696 (1997).
34. Cubeddu, L.X. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am. J. Ther. 10, 452-457 (2003).
35. Drici, M.D. & Clément, N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 24, 575-585 (2001).
36. Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D. & Lehmann, M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270, 2590-2597 (1993).
37. Corbett, A.H., Lim, M.L. & Kashuba, A.D. Kaletra (lopinavir/ ritonavir). Ann. Pharmacother. 36, 1193-1203 (2002).
38. Chung, W.H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
39. Hung, S.I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102, 4134-4139 (2005).
40. Hsu, A., Granneman, G.R. & Bertz, R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 35, 275-291 (1998).
41. Hsu, A. et al. Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47, 350-359 (2003).
42. Ng, J. et al. Pharmacokinetics of rifabutin 150 mg TIW plus lopinavir/ritonavir (LPV/r) 400/100 mg BID administered in healthy subjects. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, Netherlands, 15-17 April, 2009.
43. Boulanger, C. et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49, 1305-1311 (2009).
44. Fletcher, C.V. Drug interactions should be evaluated in patients. Clin. Pharmacol. Ther. 88, 585-587 (2010).
45. Edstein, M.D., Prasitthipayong, A., Sabchareon, A., Chongsuphajaisiddhi, T. & Webster, H.K. Simultaneous measurement of quinine and quinidine in human plasma, whole blood, and erythrocytes by high-performance liquid chromatography with fluorescence detection. Ther. Drug Monit. 12, 493-500 (1990).
46. Orlando, R., De Martin, S., Pegoraro, P., Quintieri, L. & Palatini, P. Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin. Pharmacol. Ther. 85, 319-326 (2009).
47. Nettles, R.E. et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. 42, 1189-1196 (2006).
48. Diggle, P., Liang, K., Zeger, S. Analysis of longitudinal data 2nd edn. (Oxford University Press, Oxford, UK, 2002).
49. A llqvist, A., Miura, J., Bertilsson, L. & Mirghani, R.A. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol. 63, 173-179 (2007).